Announcements Trials
Browse Landscape

Phase

Phase 2 78Phase NA 23Phase 1 20Phase 3 16Phase 1/2 15Phase 4 9Phase EARLY_PHASE1 5Phase 2/3 5

Status

Completed 5Recruiting 3Terminated 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 92Genitourinary 56Breast 48Other hematologic neoplasm 45Thoracic 41Lymphoid 40Head & Neck 21Myeloid 18Gynecologic 18CNS 14Plasma cell 12Sarcoma 9Endocrine 8Dermatologic 8Tumor-Agnostic 7Other solid neoplasm 6Classical hematology 6Other 5NET 5

Conditions

Neuroendocrine Tumors 4Somatostatinoma 1Pheochromocytoma 1Paraganglioma 1Gastroenteropancreatic Neuroendocrine Tumors 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 1Positron Emission Tomography Computed Tomography 1Axitinib 1Al18F-NOTA-octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × NET × Clear all
NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Grupo Espanol de Tumores Neuroendocrinos

Phase 2/3 Completed
256 enrolled 25 charts
EndocrineNET

Neuroendocrine Tumors

NCT00442533 2023-04-03

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Radio Isotope Therapy of America

Phase 2/3 Completed
200 enrolled
CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Somatostatinoma, Neuroendocrine Tumors

NCT03590119 2022-11-08

LUTIA

UMC Utrecht

Phase 2/3 Completed
26 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02608203 2022-10-14

GEP-NOC

Assistance Publique Hopitaux De Marseille

Phase 2/3 Completed
18 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT04552847 2022-02-17

Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors

Universitaire Ziekenhuizen KU Leuven

Phase 2/3 Completed
85 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡